# A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer

Published: 09-04-2020 Last updated: 08-04-2024

The primary study objective is to compare: - Per-patient detection rate of 18F-DCFPyL PET/CT versus that of 18F-FCH PET/CT. The secondary objectives are to assess: - Impact on patient treatment/management. - Per-region detection rate of 18F-DCFPyL...

**Ethical review** Approved WMO

**Status** Recruitment stopped

**Health condition type** Other condition **Study type** Interventional

# **Summary**

#### ID

NL-OMON55231

#### Source

ToetsingOnline

Brief title PYTHON

## **Condition**

- Other condition
- Endocrine neoplasms malignant and unspecified

#### **Synonym**

Biochemical recurrent prostate cancer, prostate cancer

#### **Health condition**

Biochemical recurrent prostate cancer

## Research involving

Human

## **Sponsors and support**

**Primary sponsor:** Curium PET France

Source(s) of monetary or material Support: Curium PET France

## Intervention

Keyword: 18F-DCFPyL, 18F-Fluoromethylcholine, PET/CT scan, Prostate cancer

## **Outcome measures**

## **Primary outcome**

Primary endpoint:

Per-patient detection rate of 18F-DCFPyL PET/CT and 18F-FCH PET/CT for recurrence (either local, regional or distant), based on the independent central reading. The detection rate is defined as the ratio between the number of patients defined as positive at patient level by at least 2 independent readers, and the total number of assessed patients.

### **Secondary outcome**

Secondary endpoints:

- Impact on patient treatment/management.
- Per-region detection rate of 18F-DCFPyL PET/CT versus that of 18F-FCH PET/CT.
- Sensitivity and specificity of 18F-DCFPyL PET/CT versus that of 18F-FCH PET/CT on a per-patient and per-region basis, using composite SOR.
- Concordance rate between 18F-DCFPyL PET/CT and 18F-FCH PET/CT for regions using composite SOR.
- Safety of 18F-DCFPyL versus that of 18F-FCH

Ten regions will be assessed:

- prostate bed (T),
- pelvic lymph nodes (N),
- retroperitoneal lymph nodes, supradiaphragmatic lymph nodes (M1a),
- bone (M1b), five subcategories will be assessed: \*spine\*, \*ribs, sternum and scapula\*, \*iliac and sacrum\*, \*femurs and humerus\*, \*others\*,
- other organ (M1c).

# **Study description**

## **Background summary**

Prostate cancer (PCa) is recognized as one of the principal medical problem the male population is facing. Most men dying of prostate cancer succumb to metastatic and/or recurrent disease. Moreover, rising PSA after initial definitive therapy (known as biochemical recurrence (BCR) of PCa) may occur in 20-30% of prostate cancer patients within 5 years, before a more definitive diagnosis of metastatic disease can be established by conventional imaging modalities. The key question in case of BCR remains whether the PSA rise is reflective of locally confined recurrence or is caused by distant metastatic disease. Correct identification is essential for further treatment planning because, in local recurrence or loco regional lymph node metastasis, potentially curative local treatment may still be possible, whereas in distant metastasis, watchful waiting or eventually (palliative) systematic treatment should be considered.

While identification of biochemical recurrence (BCR) post therapy can be achieved with the prostate specific antigen (PSA) test, localization of recurrence can be challenging with conventional imaging modalities, like MRI or CT scans, that can\*t match the sensitivity of this blood test.

PET-CT has overcome many limitations of conventional imaging, resulting in more accurate assessment of patients with BCR. With a new class of positron emission tomography (PET) radiopharmaceuticals targeting the prostate specific membrane antigen (PSMA), it has become feasible to detect recurrent or metastatic prostate cancer that is otherwise occult on conventional imaging modalities. PSMA is a transmembrane glycoprotein expressed by virtually all prostate cancers, and its expression is further increased in metastatic and

hormone-refractory prostate carcinomas.

Various radiolabeled anti-PSMA monoclonal antibodies have been used to detect prostate cancer nodal metastasis and recurrence. 18F-DCFPyL is a radiolabeled small molecule that binds to the extracellular domain of prostate-specific membrane antigen (PSMA) with high affinity.

In this study, we aim to determine the detection rate of 18F-DCFPyL PET/CT in patients with first biochemical recurrence and assess the clinical impact of 18F-DCFPyL PET/CT in patient management and to evaluate the safety of this radiopharmaceutical for clinical use.

## Study objective

The primary study objective is to compare:

- Per-patient detection rate of 18F-DCFPyL PET/CT versus that of 18F-FCH PET/CT.

The secondary objectives are to assess:

- Impact on patient treatment/management.
- Per-region detection rate of 18F-DCFPyL PET/CT versus that of 18F-FCH PET/CT.
- Sensitivity and specificity of 18F-DCFPyL PET/CT versus that of 18F-FCH PET/CT on a per-patient and per-region basis, using a composite SOR.
- Concordance rate between 18F-DCFPyL PET/CT and 18F-FCH PET/CT for regions using a composite SOR.
- Safety of 18F-DCFPyL versus that of 18F-FCH

## Study design

This is a prospective, open label, cross-over, comparative study. The study population is diagnosed in the past with histopathologically confirmed prostate adenocarcinoma, for which curative therapy is received. The results of the PSA test suspects that the patient has biochemical recurrence of prostate cancer, defined by:

- PSA \* 0.2 ng/mL confirmed by a subsequent PSA value of \*0.2 ng/mL, if the patient has previously been treated by radical prostatectomy +/- eLND,
- Rise of PSA > 2 ng/mL above the nadir after therapy, regardless of the serum concentration of the nadir, if the patient has previously been treated by curative radiation therapy (EBRT or brachytherapy).

Patients are randomized to determine the order of the 2 radiodiagnostic agents to be used.

The evaluation of the PET / CT scans will be performed blinded by a central reading center.

#### Intervention

In this study, 2 radiodiagnostic tracers, intravenously administered, will be used:

- 18F-DCFPyl
- 18F-Fluoromethylcholine.

## Study burden and risks

Biochemical recurrence (BCR) of prostate cancer occurs in 20-30% of the patient before a more definitive diagnosis of metastatic disease can be established by conventional imaging modalities. With a PET-CT, using the radiopharmaceutical tracer [18F]-DCFPyL it is thought to early detect recurrent and/or metastatic prostate cancer in patients with BCR

Two PET/CT scans will be made during the study, one with the radiopharmaceutical study product [18F]-DCFPyL and one with the radiopharmaceutical product [18F]-Fluoromethylcholine.

The general risks related to any PET scan are especially:

- Irradiation risks which are very low. Indeed, the main risk related to irradiation concerns the kidneys which are the critical organs as they will participate in the elimination of the diagnostic product from the body. Therefore, the maximum dose to be injected was chosen so that it will be lower than the irradiation received during an x-ray of the kidneys.
- Allergic reactions that may occur but remain extremely low.

The risk related to the PET scan with [18F]-DCFPyL:

- [18F]-DCFPyL has been used in the US and in the Netherlands in many clinical studies, the product appeared to be well tolerated and no severe side effects were reported in those studies.
- Based on those studies, the patient may experience fatigue, dysgeusia or headache.

The risk related to the PET scan with [18F]-Fluoromethylcholine:

- To date, no side effects have been described.

With a PET scan X-ray radiation and radioactive substances are used. The total radiation burden in this study is 17.2 mSv. In comparison: the background radiation in the Netherlands is ~2.5 mSv, per year.

The radiation used during the study may cause damage to the patient's health.

#### Blood draw:

The risks involved in drawing blood from a vein may include, but are not limited to, momentary discomfort and/or pain at the site of the blood draw, possible bruising, redness, and swelling around the site, bleeding at the site, feeling of lightheadedness when the blood is drawn, and rarely, an infection at the site of the blood draw.

The following procedures will be performed during the study:

- undergo physical examination (1x)
- measurement of vital signs (6x)

## **Contacts**

#### **Public**

Curium PET France

rue Marie Curie 3 Saint-Beauzire 63360 FR

**Scientific** 

Curium PET France

rue Marie Curie 3 Saint-Beauzire 63360 FR

## **Trial sites**

## **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

## Age

Adults (18-64 years) Elderly (65 years and older)

## Inclusion criteria

- 1. Male.
- 2. Age \* 18 years.
- 3. Histopathological proven prostate adenocarcinoma per original diagnosis.
- 4. First suspected recurrence of prostate cancer based on rising prostate-specific antigen (PSA) after initial curative therapy with radical prostatectomy of PSA \* 0.2 ng/mL confirmed by a subsequent PSA value of \*0.2 ng/mL or with radiation therapy (external beam or brachytherapy) of PSA > 2
  - 6 A Prospective Study on 18F-DCFPyL PET/CT Imaging in Biochemical Recurrence of Pr ... 23-06-2025

ng/mL above the nadir after therapy regardless of the serum concentration of the nadir.

- 5. Able and willing to provide informed consent and comply with protocol requirements
- 6. Patient who can undergo all study procedures per Investigator\*s point of view
- 7. Patient with social insurance cover.

## **Exclusion criteria**

- 1. ECOG > 2
- 2. History of previous salvage therapies (including salvage radiotherapy or salvage lymph node dissection)
- 3. History of adjuvant radiotherapy
- 4. History of cryotherapy, high-intensity focused ultrasound (HIFU)
- 5. Other active malignant tumour
- 6. Treatment with Androgen Deprivation Therapy (ADT) in the past 30 days or ongoing
- 7. Treatment with colchicine in the past 8 days or ongoing
- 8. Treatment with hematopoietic colony stimulating factors (CSF) in the past 5 days or ongoing
- 9. Unable to lie supine for imaging
- 10. Known allergy to investigational or reference products or to any excipients
- 11. Unable to provide written consent (linguistic or psychological inability)
- 12. Participation in another clinical study within one month prior to inclusion
- 13. Uncooperative, in the Investigator's opinion.
- 14. Subjects deprived of their freedom by administrative or legal decision or who are under quardianship

# Study design

## Design

Study phase: 3

Study type: Interventional

Intervention model: Crossover

Allocation: Randomized controlled trial

Masking: Open (masking not used)

Control: Active

Primary purpose: Diagnostic

## Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 12-10-2020

Enrollment: 30

Type: Actual

## Medical products/devices used

Product type: Medicine

Brand name: 18F-DCFPyL

Generic name: 18F-DCFPyL

Product type: Medicine

Brand name: Fluorocholine (18F) Cis bio international

Generic name: Fluorocholine (18F) Chloride

Product type: Medicine

Brand name: PROSTATEP 500 MBq/mL

Generic name: Fluorocholine (18F)

## **Ethics review**

Approved WMO

Date: 09-04-2020

Application type: First submission

Review commission: METC Amsterdam UMC

Approved WMO

Date: 18-06-2020

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 19-08-2020

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 18-09-2020

Application type: First submission

Review commission: METC Amsterdam UMC

Approved WMO

Date: 23-10-2020

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 19-11-2020

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 09-04-2021

Application type: Amendment

Review commission: METC Amsterdam UMC

Approved WMO

Date: 24-06-2021

Application type: Amendment

Review commission: METC Amsterdam UMC

# **Study registrations**

# Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register ID

EudraCT EUCTR2020-000121-37-NL

CCMO NL72802.029.20